A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its ...

Novartis could soon face generic competition for Entresto after judge's ruling.

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key ...

Novartis Pharmaceuticals Corp. convinced the Federal Circuit to temporarily block MSN Pharmaceuticals Inc. from launching a ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...

A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto.